LONDON, GREATER LONDON, UNITED KINGDOM, November 22, 2024 /EINPresswire / -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-limited time only!

All the time in the world is never enough time. You especially notice this when you don't know if you'll get another day.

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

PET imaging using a radiolabeled antibody picked up clear cell renal cell carcinoma and could help avert unnecessary biopsies ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, ...

BRCA mutations are inextricably linked with breasts, but they can also lead to cancer in the pancreas, the prostate, and ...

Q: Is PSA testing still the best screening test for prostate cancer? A: While middle-age men should consider the pros and ...

Researchers have identified a new role for the enzyme EZH2 in promoting the progression of aggressive, treatment-resistant ...

Hirst III Professors of Oncology in Pathology and members of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. The scientists found that the absence of a protein called PKCλ/ι in ...

This Movember, prioritize your health by getting screened for prostate cancer. Early detection saves lives—learn why regular ...

In its early stages, prostate cancer rarely causes noticeable symptoms. By the time warning signs like difficulty urinating ...